Mirati signs up to precision medicine trial in lung cancer

19 November 2018

Sitravatinib, a drug from Californian cancer specialist Mirati Therapeutics (Nasdaq: MRTX), is to be tested as part of Cancer Research UK’s Stratified Medicine Programme.

Cancer Research UK’s Stratified Medicine Programme and its associated precision medicine Phase II trial, the National Lung Matrix Trial, seeks to answer research questions in this disease space.

Sitravatinib targets genetic vulnerabilities that are collectively found in around 5.5% of non-small cell lung cancer patients (NSCLC) and could offer a new, more effective, treatment option for some patients.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK